Biotech of the Week: Immunicum, Immuno-oncology made in Sweden

20/05/2016 - 2 minutes

We like Scandinavia so much we just don’t want to leave, therefore, we’re heading back East again!

This time, Gothenburg is our destination. Being the second biggest city in Sweden and having the biggest harbor in the Northern countries (and once the hosting city for the Eurovision Song Contest in 1985) it is also where Immunicum – our Biotech of The Week – is based.


City: Gothenburg (Sweden)

Founded: 2002

Employees: 5 (as of 11/2015)

Financial Data: €56M Market Cap (on 19/05/2016)

CEO: Jamal El-Mosleh


Mission: Founded in 2002,  Immunicum’s line of work focuses on the development of cancer immunotherapies based on three different platform technologies. They aim to advance product candidates which are already in Phase II trials so they can license them to out to Big Pharma.

With five projects on their pipeline, Immunicum is giving special focus to three of them with,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member